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ABSTRACT: The longitudinal association between glycated hemoglobin (HbA1c) and different courses of depressive 
symptoms is understudied. This study aimed to identify different trajectories of depressive symptoms and investigate 
the relation of HbA1c with the risk of increasing and high-stable depressive symptoms. In the China Health and 
Retirement Longitudinal Study, depressive symptoms were measured using the 10-item Center for Epidemiological 
Studies-Depression scale in three visits (years: 2011, 2013 and 2015) among 9804 participants (mean age 
60.0 ± 9.0 years). Group-based trajectory modeling was used to identify trajectories of depressive symptoms. HbA1c 
was measured at baseline and categorized five groups according to the respective quintile. Multinomial logistic 
regression was fitted to examine this relationship. Four distinct trajectories of depressive symptoms were identified: 
low symptoms (n=6401, 65.29%); decreasing symptoms (n=1362, 13.89%); increasing symptoms (n=1452, 14.81%); 
and high symptoms (n=1452, 14.81%). Adjusting for demographic, health-related, and cognitive factors, the risk ratio 
(95% confidence interval) pertaining to the highest HbA1c (Quintile 5) for decreasing, increasing, and high symptoms 
of depression versus low symptoms was 1.01 (0.82-1.25), 1.12 (0.92-1.36), and 1.39 (1.04-1.86) compared with the lowest 
HbA1c (Quintile 1), respectively. We observed a J-shaped relationship between HbA1c and high depressive symptoms, 
with the lowest risk at a HbA1c concentration of 5.0%. In summary, in this large population-based cohort, high levels 
of glycated hemoglobin concentrations were associated with a higher risk of increasing and high-stable symptoms of 
depression. 
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Depression symptoms are highly prevalent and impact the 
quality of life of those struggling from them [1]. 
Especially, in China, the prevalence of depressive 
symptoms among the elderly has been reported to be up 
to 22.7% [2]. Moreover, depressive symptoms that 
increase over time are also associated with a range of 
adverse outcomes, including cardiovascular diseases [3, 
4], dementia [5] and all-cause mortality [6]. 
Understanding risk factors attributed to depressive 
symptoms is a major public health priority; however, 
potential risk factors for depression symptoms remain 
unclear.  
Several cohort studies [7-9] and meta-analysis [10-
12] have revealed that depressive symptoms were 
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associated with a high risk of diabetes mellitus. 
Additionally, a recent meta-analysis also shows that 
diabetes mellitus increased the risk of depression by 25% 
[13]. This suggests that the association between 
depressive symptoms and diabetes mellitus is more 
complex and may be bidirectional[8]. However, in most 
studies, depressive symptoms are assessed at a single 
point time (at baseline), and hence these studies may not 
have fully captured the longitudinal pattern of depressive 
symptoms.  
Glycated hemoglobin (HbA1c) is considered as the 
gold standard measurement of glycemic control for 
diabetes mellitus patients, reflecting glucose exposure 
over the previous two to three months[14]. Previous 
studies found HbA1c is associated with depressive 
symptoms [15, 16]. Furthermore, these studies neglect the 
relapsing and remitting nature of depressive symptoms. 
However, very few studies have provided information that 
describes the relationship between HbA1c and the 
longitudinal pattern of depressive symptoms in the 
Chinese population.  
Therefore, the aims of this study were to use repeated 
measures of depressive symptoms in three visits from 
China Health and Retirement Longitudinal Study 
(CHARLS), a nationwide representative cohort study, to 
identify the different trajectories of depressive symptoms, 
and investigate a possible link between HbA1c and the 
trajectory of depressive symptoms. We hypothesize that 
high levels of HbA1c is associated with increasing and 
high-stable depressive symptoms. 
 
MATERIALS AND METHODS 
 
Study design and population 
 
CHARLS is a population-based, prospective cohort study 
of 17708 middle-aged and elderly (main respondents ≥45 
years) individuals from 150 counties within 28 provinces 
in China[17]. The first visit was accomplished in 2011 
(visit 1), and subsequently two follow-up visits carried out 
after that, each nearly two years apart (visit 2 in 2013, visit 
3 in 2015). The present analysis was limited to 11847 
participants who agreed to perform blood examinations in 
the visit 1. Out of those participants, 11532 participants 
who stored whole-blood samples were available for 
measurement of glycated hemoglobin or fasting glucose. 
Additionally, 1521 participants were excluded due to 
incomplete data on Center for Epidemiologic Studies 
Depression Scale (CES-D) during the 2011-2015 period, 
as well as 207 main respondents’ spouses who were under 
45 years are excluded (Supplementary Fig. 1). Our final 
sample size was 9804 persons. The study protocol was 
approved by the institutional review board of Peking 
University. All participants provided written informed 
consent. 
 
Assessment of depressive symptoms 
 
Depressive symptoms were evaluated using the 10-item 
Center for Epidemiologic Studies Depression Scale (CES-
D) [18]. Participants were asked how often they had 
experienced any of the ten symptoms listed during the past 
week. The answers for the 10 questions were ranged on a 
scale from: rarely (0-1 day); to some days (1-2 days); to 
occasionally (3-4 days); and to most of the time (5-7 
days). Scores ranged from 0 for rarely to 3 points for most 
of the time were assigned for each item and the total 
scores were calculated and ranged from 0 to 30. CES-D 
had been shown good validity and reliability in the 
CHRLS [19]. For the current analysis, missing CES-D 
exceeding 2 items were excluded. We only included 
participants who had complete assessments of depression 
at visits 1, and at least had a one-time assessment at visits 
2 or 3.  
 
Measurement of glycated hemoglobin 
 
A specimen of whole blood was stored at -80 ◦C in a deep 
freezer and sent to the Youanmen Center for Clinical 
Laboratory of Capital Medical University. Total HbA1c 
was measured using standard methods of boronate affinity 
high performance liquid chromatography. The coefficient 
of variation of within assay and between assay was 1.90% 
and 2.10%, respectively. The detection limits of the assay 
were ranged from 0.0% to 40.0%. Detailed information 
regarding blood sample collection, processing, 
transportation, storage, the technicalities of the blood 
analysis, as well as the quality control and the external 
quality assessment for the laboratory has been described 
in the CHALRS Blood Sample Users’ Guide 
(http://charls.pku.edu.cn/uploads/document/2011-charls-
wave1/application/blood_user_guide_en_20140429.pdf). 
 
Covariates 
 
Sociodemographic information, lifestyle behaviors and 
medical history were obtained using a face-to-face 
standard questionnaire and physical examination [17]. 
The sociodemographic characteristics included age, 
gender, living area (urban and rural), education and 
marital status (married and unmarried). Self-reported 
education was coded as a four levels factor (< primary 
school, primary school, middle school, and ≥ high 
school). Each participant was asked two questions: “Have 
you smoked at least 100 cigarettes in your lifetime?” and 
“Do you currently smoke cigarettes, even occasionally? 
The options for possible answer to the questions were 
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either if it was true or not. Smoking status consisted of 
never, former smoker, or current smoker. Alcohol 
consumption was determined from one question: “How 
often did you drink alcoholic beverages in the past?” The 
answer included never, <1, and ≥1 time/month. Self-
reported physician diagnosed diseases included cardiac 
diseases, stroke, hypertension, diabetes mellitus, 
dyslipidemia and lung diseases. Antidepressant drugs 
were recoded and updated during 2011-2015. Trained and 
certified health professionals conducted a physical 
examination. Weight was measured using the OmronTM 
HN-286 scale, and height was measured using SecaTM213 
stadiometer. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in meters squared. 
Obesity was defined as those who had a BMI over 28.0 
kg/m2 [20]. Blood pressure was measured using the 
OmronTM HEM-7200 Monitor. Three times blood 
pressure measurements were taken after the participants 
were seated, and rested quietly for >5 minutes and the 
average value was obtained. Cognition scores was 
consisted of immediate and delayed recall of a 10-word 
list (20 points), serial 7 subtractions (5 points), orientation 
(1 point each for year, month, date, day of the week, and 
season) and drawing a picture (1 point). Then, total scores 
were calculated, which were ranged from 0 to 31, where 
higher scores indicated better cognitive function[17]. 
Overnight fasting blood samples were collected and tested 
for high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), glucose, high-
sensitivity C-reactive protein (hs-CRP), and creatinine by 
standard methods [21]. The estimated glomerular 
filtration rate (eGFR) was calculated based on the Chronic 
Kidney Disease Epidemiology Collaboration equation 
(CKD-EPI-2009) [22]. 
 
Statistical analysis 
 
Trajectories of depressive symptoms were the main 
outcomes. Trajectories of depressive symptoms were 
determined using group-based trajectory modeling 
(GBTM), an application of finite mixture modeling to map 
the developmental course of symptoms over time or 
age[23, 24]. We conducted a censored normal distribution 
model using Stata traj plugin [25] to estimate the mean 
trajectories of CES-D scores (measured at year 0, 2, 4) 
across three visits. The number and the shape of 
trajectories of depressive symptoms were identified based 
on a priori. Firstly, the average posterior probabilities of 
each trajectory group were ≥0.70 and the sample size was 
≥5.0% of the population [23]. Secondly, nonsignificant 
cubic and quadratic terms were removed from trajectories 
in each model, but linear parameters were retained 
irrespective of significance. Third, Bayesian Information 
Criterion (BIC) value and log Bayes factor was calculated 
and used to determine the best numbers and shapes of the 
trajectories. The value of log Bayes factor ≥10 was 
considered a “very strong” indicator where the more 
complex model was superior to with fewer 
trajectories[23]. Later, trajectories of depressive 
symptoms were plotted over follow-up time.  
The exposure variable was glycated hemoglobin, and 
categorized according to quintiles as follows: Quintile 1 
(≤4.8%); Quintile 2 (4.9-5.0%); Quintile 3 (5.1-5.2%); 
Quintile 4 (5.3-5.5%); and Quintile 5 (≥5.6%). Linear 
trends across the 5 groups were evaluated using the 
generalized linear model. Multinomial logistic regression 
was used to calculate the adjusted risk ratios (RR) of 
decreasing, increasing, and high symptoms of depression 
compared with low symptoms according to glycated 
hemoglobin categories, while simultaneously adjusting 
for confounding covariates. For confounder adjustment, 5 
models were evaluated. Model 1 was minimally adjusted 
for age and gender. Model 2 was adjusted for the 
additional socio-demographics of marital status, 
educational level, living area, and health behaviors of 
smoking and alcohol frequency. Model 3 was further 
adjusted the baseline health conditions including 
hypertension, diabetes mellitus, cardiac disease, stroke, 
dyslipidemia, lung disease, and obesity. Then, we 
sequentially added other covariates, including cardiac 
markers (Model 4), baseline cognition scores and 
antidepressant use over 4 years (Model 5). 
In addition, we evaluated the dose-response 
relationship between glycated hemoglobin, as continuous 
change, and each trajectory of depressive symptoms using 
restricted cubic splines[26] with 4 knots corresponding to 
the 5th, 35th, 65th, and 95th percentiles of glycated 
hemoglobin distribution. The likelihood-ratio tests were 
used to assess whether it exited in a nonlinear trend.  
Sensitivity analyses were also conducted: 1) changing 
glycated hemoglobin categories of <4.5%, 4.5-5.0%, 5.1-
5.5%, 5.6-6.0%, and >6.0%, respectively; 2) excluding 
participants who had treatments for depression or 
diabetes; 3) limited to those participants who were free of 
depression symptoms (CES-D scores <10[27]) at 
baseline. We explored the relationship between glycated 
hemoglobin and incidence of depressive symptoms at 
visit 3 (year 2015). Lastly, to test whether the associations 
differed between gender, gender-specific analyses were 
performed for male and female, separately. Subsequently, 
a multiplicative term between gender and quantile of 
HbA1c was added in the full-adjusted model and the 
interaction was tested by a likelihood ratio test. 
All analyses were performed with Stata software 
(version 14.0; Stata Corp., College Station, TX). A two-
sided P value <0.05 was considered statistically 
significant. 
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Table 1. Baseline Characteristics of the Study Participants According to the Quintile of Glycated Hemoglobin (HbA1c). 
 
Characteristic* 
Quintile 1 
(≤4.8 %) 
Quintile2 
(4.9-5.0 %) 
Quintile 3 
(5.1-5.2 %) 
Quintile 4 
(5.3-5.5 %) 
Quintile 5 
(≥5.6 %) 
P for 
Trend 
No. of participants  2258 1815 1904 2022 1805  
Glycated hemoglobin, % 4.6 ± 0.2 5.0 ± 0.0 5.1 ± 0.1 5.4 ± 0.1 6.4 ± 1.2 <0.001 
Age, yr 58.2 ± 9.4 58.4 ± 9.1 59.0 ± 9.0 59.4 ± 8.8 59.8 ± 8.6 <0.001 
Male gender, no. (%)  1088 (48.2) 864 (47.6) 873 (45.9) 925 (45.7) 801 (44.4) 0.008 
Married, no. (%)  1997 (88.4) 1607 (88.5) 1700 (89.3) 1787 (88.4) 1609 (89.1) 0.587 
Urban, no. (%)  796 (35.3) 623 (34.3) 664 (34.9) 695 (34.4) 744 (41.2) <0.001 
Educational level, no. (%)       <0.001 
   <Primary school 974 (43.1) 827 (45.6) 895 (47.0) 1012 (50.0) 839 (46.5)  
   Primary school 542 (24.0) 379 (20.9) 433 (22.7) 455 (22.5) 406 (22.5)  
   Middle school 480 (21.3) 427 (23.5) 391 (20.5) 335 (16.6) 371 (20.6)  
   ≥High school 262 (11.6) 182 (10.0) 185 (9.7) 220 (10.9) 189 (10.5)  
Smoking status, no. (%)       0.069 
   Never 1357 (60.1) 1108 (61.0) 1165 (61.2) 1213 (60.0) 1141 (63.2)  
   Former smoker 189 (8.4) 157 (8.7) 164 (8.6) 176 (8.7) 171 (9.5)  
   Current smoker 712 (31.5) 550 (30.3) 575 (30.2) 633 (31.3) 493 (27.3)  
Alcohol frequency, no. (%)       <0.001 
   Never 1441 (63.8) 1207 (66.5) 1277 (67.1) 1379 (68.2) 1291 (71.5)  
   <1 time/month 199 (8.8) 135 (7.4) 155 (8.1) 151 (7.5) 129 (7.1)  
   ≥1 time/month 618 (27.4) 473 (26.1) 472 (24.8) 492 (24.3) 385 (21.3)  
Physician diagnosed diseases, no. (%) 
Hypertension  487 (21.6) 433 (23.9) 449 (23.6) 528 (26.1) 578 (32.0) <0.001 
Diabetes mellitus  57 (2.5) 43 (2.4) 43 (2.3) 91 (4.5) 337 (18.7) <0.001 
Cardiac diseases  238 (10.5) 200 (11.0) 241 (12.7) 268 (13.3) 283 (15.7) <0.001 
Stroke  46 (2.0) 32 (1.8) 31 (1.6) 41 (2.0) 52 (2.9) 0.079 
Dyslipidemia  178 (7.9) 143 (7.9) 183 (9.6) 188 (9.3) 253 (14.0) <0.001 
Lung diseases  227 (10.1) 174 (9.6) 192 (10.1) 224 (11.1) 179 (9.9) 0.559 
BMI, kg/m2 23.1 ± 3.8 23.3 ± 3.8 23.4 ± 3.7 23.7 ± 4.2 24.6 ± 4.1 <0.001 
Obesity, no. (%)  463 (20.5) 377 (20.8) 379 (19.9) 421 (20.8) 530 (29.4) <0.001 
Systolic BP, mm Hg 129.9 ± 20.4 129.7 ± 20.2 129.8 ± 20.0 130.5 ± 20.8 132.6 ± 19.8 <0.001 
Diastolic BP, mm Hg 75.6 ± 11.7 75.7 ± 11.8 75.7 ± 11.5 75.6 ± 11.7 76.8 ± 10.8 0.009 
Fasting glucose, mg/dl 100.2 ± 19.4 101.7 ± 17.0 104.3 ± 20.2 107.1 ± 20.0 140.3 ± 65.3 <0.001 
LDL Cholesterol, mg/dl 109.9 ± 33.2 115.6 ± 33.0 117.6 ± 35.9 118.2 ± 34.8 122.2 ± 36.6 <0.001 
HDL Cholesterol, mg/dl 51.6 ± 15.4 51.9 ± 15.0 50.9 ± 14.5 51.9 ± 16.0 48.5 ± 15.2 <0.001 
C-reactive protein, log 0.0 ± 1.1 0.1 ± 1.0 0.1 ± 1.0 0.2 ± 1.1 0.4 ± 1.1 <0.001 
Estimated GFR, ml/min/1.73 m2 93.5 ± 14.6 93.1 ± 14.1 91.8 ± 14.8 92.2 ± 14.8 90.9 ± 15.2 <0.001 
Cognition scores 14.9 ± 5.2 15.0 ± 5.1 14.6 ± 5.2 14.4 ± 5.3 14.4 ± 5.3 <0.001 
Antidepressant use¶, no. (%) 16 (0.7) 8 (0.4) 10 (0.5) 15 (0.7) 14 (0.8) 0.508 
 
*Plus–minus values are means ±SD. Abbreviations: BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; C-reactive protein was measured in mg/l. 
¶ Antidepressant use was updated by every visit from 2011 to 2015. 
RESULTS 
 
Baseline characteristics of the participants according to 
the quintile of HbA1c were shown in Table 1. The overall 
mean (±SD) HbA1c of the study population was 5.26 ± 
0.81 % (5th to 95th percentile ranged from 4.50 to 6.40 
%) (Supplementary Fig. 2). The average concentrations 
for subjects in the highest quintile (Quintile 5, n=1805), 
and lowest quintile (Quintile 1, n=2258) were 4.61 ± 
0.22%, 6.40 ± 1.25%, respectively. Compared with the 
lowest quintile of HbA1c (Quintile 1), those with the 
highest quintile of HbA1c (Quintile 5) were older, and 
more likely to be female, living in urban areas, more likely 
to have had a higher education, less likely to be a current 
smoker or drinker, and more likely to have a higher BMI, 
blood pressure, fasting glucose, LDL-C, HDL-C and hs-
CRP (Table 1). Coexisting conditions were highly 
prevalent among participants who had the highest levels 
of HbA1c (Table 1). 
During the three visits, data on CES-D scores were 
available for 9804, 9360, and 9140 participants, 
respectively. 8696 had data suggesting CES-D scores at 
all three visits. Firstly, based on a priori, we conducted a 
GBTM analysis with 3 trajectories (BIC=-85859.06). We 
found 4 trajectories (BIC=-85666.43) were superior to the 
model with 3 trajectories. The log Bayes factor was 
385.26, revealing that the four-trajectory was the best fit. 
Although a model with 5 trajectories (BIC=-85577.58) 
was associated with further improvement in model fit (log 
Bayes factor=177.7), this model yielded a trajectory with 
less than 5% of participants (63.25%; 15.69%; 12.23%; 
2.28% and 6.55%, respectively). Therefore, four distinct 
trajectories of depressive symptoms were identified in 
subsequent analyses. The average posterior probabilities 
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of each trajectory group were 0.90, 0.70, 0.71 and 0.83, 
respectively. 
 
 
Figure 1. Trajectories of Depressive Symptoms from 2011-
2015. 
 
As shown in Figure 1, four depressive symptoms 
trajectories reflected the patterns of low, decreasing, 
increasing or high symptoms over 4 years. Trajectory 1, 
termed “low symptoms” (n=6401, 65.29%), which 
followed a linear trend (β0=5.10, P<0.001; β1=-0.15, 
P<0.001), represented the individuals who maintained a 
low CES-D score throughout the follow-up. Trajectory 2, 
termed “decreasing symptoms” (n=1362, 13.89%) 
followed a quadratic trend (β0=15.50, P<0.001; β1=-2.43, 
P<0.001; β2=0.19, P=0.008), in which individuals started 
at moderately high scores but then remitted. Trajectory 3, 
termed “increasing symptoms (n=1452, 14.81%)” follows 
a quadratic trend (β0=9.93, P<0.001; β1=-1.12, P<0.001; 
β2=0.61, P<0.001) in which CES-D scores increased 
slowly from year 0 to year 2, and then increased quickly 
by year 3. Trajectory 4, termed “high symptoms” (n=589, 
6.01%) follows a quadratic trend (β0=19.49, P<0.001; 
β1=-0.67 P<0.001; β2=0.25 P<0.001), in which 
individuals maintained high scores throughout.  
 
 
 
Table 2. Risk Ratios for the Association Between Quintile of Glycated Hemoglobin (HbA1c) and 
Risk of Trajectories of Depressive Symptoms * 
 
 
Low symptoms 
(n=6401) 
Decreasing symptoms 
(n=1362) 
Increasing symptoms 
(n=1452) 
High symptoms 
(n=589) 
Model 1: Adjusted for age and gender 
Quintile 1  1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Quintile 2  0.90 (0.75-1.09) 1.07 (0.89-1.28) 0.85 (0.64-1.13) 
Quintile 3  1.05 (0.88-1.25) 1.02 (0.85-1.22) 1.08 (0.83-1.41) 
Quintile 4  0.97 (0.81-1.16) 1.28 (1.08-1.52) 1.00 (0.77-1.30) 
Quintile 5  1.08 (0.90-1.30) 1.18 (0.99-1.42) 1.29 (1.00-1.67) 
Model 2: Adjusted for demographics a and health behaviors b 
Quintile 1  1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Quintile 2  0.89 (0.74-1.07) 1.05 (0.88-1.27) 0.83 (0.62-1.1) 
Quintile 3  1.04 (0.87-1.25) 1.01 (0.84-1.22) 1.08 (0.83-1.41) 
Quintile 4  0.94 (0.78-1.13) 1.26 (1.06-1.50) 0.97 (0.74-1.26) 
Quintile 5  1.12 (0.93-1.35) 1.22 (1.02-1.47) 1.37 (1.05-1.77) 
Model 3: Adjusted for demographics a, health behaviors b and baseline health conditions c 
Quintile 1  1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Quintile 2  0.89 (0.73-1.07) 1.05 (0.87-1.26) 0.83 (0.62-1.11) 
Quintile 3  1.03 (0.86-1.24) 1.00 (0.84-1.21) 1.08 (0.82-1.41) 
Quintile 4  0.92 (0.76-1.10) 1.24 (1.04-1.47) 0.93 (0.71-1.22) 
Quintile 5  1.07 (0.88-1.29) 1.18 (0.98-1.42) 1.28 (0.97-1.68) 
Model 4: Adjusted for demographics a, health behaviors b, baseline health conditions c and cardiac marker d  
Quintile 1  1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Quintile 2  0.88 (0.73-1.06) 1.05 (0.87-1.26) 0.84 (0.63-1.13) 
Quintile 3  1.03 (0.86-1.24) 1.00 (0.83-1.20) 1.12 (0.85-1.46) 
Quintile 4  0.90 (0.75-1.08) 1.22 (1.02-1.46) 0.97 (0.74-1.27) 
Quintile 5  1.05 (0.85-1.28) 1.14 (0.94-1.39) 1.46 (1.09-1.95) 
Model 5: Adjusted for demographicsa, health behaviorsb, baseline health conditionsc, cardiac markerd, 
antidepressant use and cognition scores 
Quintile 1  1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Quintile 2  0.89 (0.73-1.08) 1.05 (0.87-1.27) 0.84 (0.63-1.13) 
Quintile 3  1.02 (0.85-1.23) 0.99 (0.82-1.20) 1.10 (0.84-1.45) 
Quintile 4  0.89 (0.74-1.07) 1.21 (1.01-1.44) 0.95 (0.72-1.24) 
Quintile 5  1.01 (0.82-1.25) 1.12 (0.92-1.36) 1.39 (1.04-1.86) 
 
*Data was reported as risk ratios (95%CI) from multinomial logistic regression. a Demographic factor were age, 
gender, marital status, educational level, and living area. b Health behaviors consisted of smoking, and alcohol 
frequency. c Baseline health conditions included hypertension, diabetes mellitus, cardiac disease, stroke, 
dyslipidemia, lung disease, and obesity. d Cardiac marker consisted of systolic blood pressure, fasting glucose, 
LDL cholesterol, HDL cholesterol, log-transformed C-reactive protein and eGFR. 
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Table 3. Risk of Incident Increasing and High Depressive 
Symptoms Associated with Glycated Hemoglobin Level. 
 
Glycated 
hemoglobin, 
% 
Risk Ratios (95% CI) * 
Increasing symptoms High symptoms 
4.5 1.01 (0.89-1.14) 1.10 (0.91-1.33) 
4.8 0.99 (0.96-1.03) 1.00 (0.95-1.06) 
5.0 1.00 1.00 
5.2 1.04 (0.99-1.08) 1.08 (1.01-1.15) 
5.5 1.10 (0.99-1.21) 1.22 (1.03-1.43) 
5.8 1.14 (1.00-1.30) 1.30 (1.05-1.61) 
6.0 1.16 (1.01-1.33) 1.33 (1.05-1.68) 
6.2 1.18 (1.02-1.36) 1.35 (1.06-1.72) 
6.5 1.20 (1.04-1.40) 1.36 (1.04-1.77) 
 
*Adjusted for age, gender, marital status, educational level, living area, 
smoking, alcohol frequency, hypertension, diabetes mellitus, cardiac 
disease, stroke, dyslipidemia, lung disease, obesity, systolic blood 
pressure, fasting glucose, LDL cholesterol, HDL cholesterol, log-
transformed C-reactive protein, estimated GFR, antidepressant use and 
cognition scores. 
 
During a 4 year of follow-up, 130 (5.76%), 
91(5.01%), 120 (6.30%), 116 (5.74%) and 132 (7.31%) 
subjects developed high depressive symptoms across the 
quintile of HbA1c, respectively. Corresponding increasing 
depressive symptoms were 305 (13.51%), 266 (14.66%), 
261 (13.71%), 342 (16.91%) and 278 (15.40%). 
Individuals with a high HbA1c were significantly more 
likely to have increasing and high depressive symptoms 
compared with their counterparts with low HbA1c (Table 
2). The RR of highest HbA1c of high depressive symptoms 
was 1.37 (95% CI: 1.05-1.77) as compared with those 
with the lowest levels of HbA1c after adjusted for 
demographics and health behaviors variables. In addition, 
we further adjusted for systolic blood pressure, fasting 
glucose, LDL cholesterol, HDL cholesterol, log-
transformed hs-CRP, eGFR, antidepressant use and 
cognition scores, the multivariate-adjusted risk ratios of 
high depressive symptoms remained significant (RR:1.39, 
95% CI:1.04-1.86). Meanwhile, the risk for increasing 
symptoms of depression of highest HbA1c (Quintile 5) still 
was not statistically significant compared with Quintile 1 
(adjusted RR: 1.12, 95% CI: 0.92-1.36). The 
corresponding Quintile 4 group was at high risk of 
increasing symptoms of depression (adjusted RR: 1.21, 
95% CI: 1.01-1.44). 
We also used restricted cubic splines to estimate the 
trend in the risk for increasing and high depressive 
symptoms. The spline function for HbA1c confirmed the 
nonlinear, J-shaped relationship with the risk of high 
depressive symptoms. Whereas the association of HbA1c 
concentration with increasing depressive symptoms 
appeared to be linear throughout the range from the 5th to 
the 95th percentile of HbA1c (Fig. 2). For instance, for a 
HbA1c levels of 6.5% compared to 5%, the adjusted risk 
ratios for increasing and high depressive symptoms was 
1.20 (95% CI: 1.04-1.40) and 1.36 (95% CI: 1.04-1.77), 
respectively (Table 3). 
 
 
Figure 2. Risk of Incident Increasing and High Depressive 
Symptoms Associated with Glycated Hemoglobin Level. 
Solid curve represents estimates of the risk ratios. The dashed 
lines represent pointwise 95% confidence intervals. HbA1c of 
5% was used as the reference because it approximated the 
median values. The graphs are truncated at the 5th and 95th 
percentiles. 
 
Our results were robust in various sensitivity 
analyses. Firstly, results from this analysis using an 
alternative HbA1c category was consistent with the 
previous results; in particular, high levels of HbA1c 
(>6.0%) was still associated with a significantly increased 
risk of increasing (RR: 1.36, 95% CI: 1.03-1.79) and high 
(RR: 1.73, 95% CI: 1.14-2.63) symptoms of depression. 
(Supplementary Fig. 3). Secondly, the results remained 
essentially unchanged after excluding these individuals 
who had treatments for diabetes or depression 
(Supplementary Table 1). Thirdly, we excluded those who 
had depressive symptoms at baseline (n=3715), as well as 
participants with missing data of CES-D in visits 3 (year 
2015) (n=422). The final analytical sample was limited to 
5667 persons. During a 4-year follow-up, 1281 
(n=22.60%) incident depressive symptoms were 
identified. The adjusted risk ratios of the Quintile 4 group 
(ranged from 5.3% to 5.5%) compared with the lowest 
quantile group of HbA1c was 1.29 (95% CI: 1.12-1.49). 
Corresponding risk ratios for the highest HbA1c quantile 
was 1.12 (95% CI: 0.95-1.33) (Supplementary Table 2). 
Lastly, for male, the risk ratios of high symptoms for 
participants in the second and top HbA1c quintile were 
0.91 (95%CI: 0.55-1.51) and 1.20 (95% CI: 0.71-2.03), 
respectively. Corresponding risk ratios for female were 
0.81 (95% CI: 0.56-1.17) and 1.49 (95% CI: 1.04-2.11). 
We found a marginal difference in the association of 
quantile of HbA1c with different trajectories of depressive 
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symptoms between male and female (Likelihood-ratio 
test: χ2=18.48, P for interaction=0.102) (Supplementary 
Table 3). 
 
DISCUSSION 
 
We observed four trajectories of depressive symptoms 
characterized by low, decreasing, increasing, and high 
symptoms in a large prospective cohort of 9804 
participants during a 4-year follow-up. Individuals with 
the highest quintile of HbA1c (≥5.6%) had the higher risk 
of developing increasing and high depressive symptoms 
compared with those with the lowest quintile (≤4.8%). 
Moreover, we observed a J-shaped relation between 
HbA1c and the risk of high depressive symptoms, with the 
lowest risk at a HbA1c of 5.0% from restricted cubic 
splines analysis. 
To the best of our knowledge, four trajectories of 
depressive symptoms were firstly identified in the middle-
aged and older Chinese adults. Previously, three 
trajectories of depressive symptoms (consistently 
minimal, moderate and increasing, and high and 
increasing symptoms) were identified with four CES-D 
measures from baseline to year 5 among 2488 older adults 
from the Health ABC prospective cohort study [28]. Five 
trajectories of depressive symptoms (low, decreasing, 
remitting, increasing, and high depressive symptoms) 
were also observed in the Rotterdam Study [5, 29]. 
Differences of shape and the number of trajectories of 
depressive symptoms were was due to the time of CES-D 
measurements as well as the follow-up time. We noted 
that, in the current study that, among the 9804 participants 
aged ≥60 years, 6.01% of individuals had the increasing 
and high-stable symptoms of depression respectively. 
Prospective cohort studies had demonstrated that 
individuals with increasing or high-stable symptoms of 
depression had a higher risk of dementia [5, 28]. 
Therefore, physicians should pay more attention to these 
individuals and treat positively depressive symptoms in 
order to reduce the burden of dementia in the clinical 
practice.  
There has been a sizable literature that reported on the 
association between diabetes and elevated depressive 
symptoms [8, 13, 15, 16, 30]; however, research related to 
the association between HbA1c and the incidence of 
depressive symptoms is limited. For example, no 
significant association was observed in the English 
Longitudinal Study of Aging after adjusted full covariates 
(OR: 1.08, 95%: 0.91-1.29 per 1% HbA1c increment) 
(Hamer et al., 2011). In addition, in the Health, Aging, and 
Body Composition Study, HbA1c ≥7% did not increased 
the risk of depressive symptoms (RR: 1.21, 95% CI: 0.94-
1.55), whereas high HbA1c was associated with a two-fold 
risk of recurrent depressive symptoms (RR: 2.10, 95% CI: 
1.36-3.22) compared with HbA1c <7% during a mean 
follow-up of 5.9 years among older person aged from 70-
79 years. This indicated that single measures of depressive 
symptoms may be inaccurate, and suggests that 
depressive symptoms seem to fluctuate over time. 
Additionally, a recent study conducted by Ravona-
Springer et al. revealed that the long-term variability in 
HbA1c was associated with more subsequent depressive 
symptoms [31]. This was consisted with our findings. 
However, in this study[31], depressive symptoms was 
only measured using Geriatric Depression Scale (GDS-
15) at baseline and the impact of the variability in HbA1c 
on the incidence of depressive symptoms was unclear. In 
our study, HbA1c was only available at baseline, and the 
association between the long-term change of HbA1c and 
the longitudinal pattern of depressive symptoms is 
required to be validated in a large population-based 
longitudinal study.  
Another interesting finding was that HbA1c also was 
associated with a high risk of an increasing depressive 
symptoms trajectory. Previous studies have shown that 
poor glycemic control at baseline was associated with 
increased risk for the incidence of depressive symptoms 
[15, 16, 32]. To confirm the findings, we also repeated the 
analysis among the non-depressed individuals and 
examined the role of HbA1c as a risk for new-onset 
depressive symptoms over a 4-year follow-up period. 
However, the highest risk of depression was observed at 
HbA1c levels of 5.3-5.5% (Quintile 4), rather than the 
highest Quintile (≥5.6 %). This finding had some 
discrepancies with previously findings related to the 
threshold of HbA1c [16, 33], which may due to the 
difference in the study design, the definition of increasing 
symptoms of depression, the distribution and 
categorization of HbA1c in the study population. Overall, 
we found HbA1c was linked to increasing symptoms of 
depression. Nonetheless, more research is needed to 
examine this association. Increasing symptoms of 
depression was meant to be emphasized, which also 
reflected glycemic control [32, 34] and increased the risk 
of diabetes [35], dementia [5, 28] and all-cause mortality 
[29]. 
Our findings further demonstrated that baseline 
HbA1c was associated with increasing and high depressive 
symptoms. Results were not affected by further 
adjustment for sociodemographic, history of diabetes, 
fasting glucose, and other confounders that related to 
depressive symptoms. In addition, depressive symptoms 
and cognitive decline were coexisting in late-life [36]. The 
relationship was robust after adjusting for cognitive 
scores. To account for bias due to use of antidepressant 
and/or antidiabetic medication, we repeated the analysis 
after excluding those relevant participants. The results 
remained considerably unaltered. Lastly, a slight stronger 
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association between HbA1c and depressive symptoms was 
observed among female, however, gender differences 
were not statistically significant (P for interaction = 
0.102). This may be due to different levels of estrogen 
[37]. The findings were consistent with a previously study 
conducted in the Nurses’ Health Study cohort [38]. 
The mechanisms underlying the relationship of 
HbA1c with subsequent risks of high symptoms of 
depression remain unclear. Firstly, the “vascular 
depression” hypothesis may explain the relationship [39]; 
HbA1c reflects the glycemic control for diabetes patients, 
and brain vasculature and the functional area may be 
mostly vulnerable to worse glycemic control [40].This 
may be related to the process of depression. Secondly, 
late-life risk factors, including smoking, obesity, and 
chronic diseases were both associated with high HbA1c 
and depressive symptoms [41]. 
Several limitations in our study should be noted. First, 
although HbA1c predicted the incidence of high 
depressive symptoms, the causal relationship between 
HbA1c and depressive symptoms has not been fully 
established. Due to this study being observational in 
nature, residual confounding could not be fully 
eliminated. Besides, the association was based on single 
glycated hemoglobin measurements at the baseline as 
well as the fact that the relationship of variability in HbA1c 
over years, with subsequent increasing and high-stable 
depressive symptoms could not be examined. Major 
strengths of our study were that it was the largest, 
nationwide population-based cohort study, as well it 
obtained a high response rate in CES-D measures (89% 
for all three visits). Moreover, the study design of 
CHARLS was referred to the Health and Retirement 
Study [42] and comprehensive and rigorous 
measurements of risk factors were collected. This gave us 
an opportunity to adjust more potential confounding 
variables. 
 
Conclusions 
 
In summary, different trajectories of depressive symptoms 
were identified by repeated measures of CES-D from 
China Health and Retirement Longitudinal Study. Our 
study findings suggest that clinicians should be aware of 
the increased risk of increasing and elevated high 
depressive symptoms for individuals with high HbA1c, 
irrespective of the history of diabetes. 
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